Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Lower doses of betaine (2-8 g/day) effectively reduced liver injury markers in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and elevated ALT. These findings suggest betaine is a safe and promising treatment for MASLD.
Area Of Science
- Hepatology
- Metabolic Disorders
- Pharmacology
Background
- Previous trials showed 20 g/day of betaine reduced liver injury in non-alcoholic steatohepatitis (NASH).
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern.
- Elevated alanine aminotransferase (ALT) is a key indicator of liver distress in MASLD.
Purpose Of The Study
- To evaluate the safety and efficacy of lower betaine doses (1-8 g/day) in MASLD patients.
- To determine optimal betaine dosage for reducing liver injury markers in MASLD.
Main Methods
- Three pilot trials involving participants with clinically diagnosed non-cirrhotic MASLD and ALT ≥50 U/L.
- Doses tested: 1 g/day (24 weeks), 2 g/day (24 weeks), 4 g/day (12 weeks), and 8 g/day (12 weeks).
- Primary outcome: Percent decline in the abnormal component of ALT; secondary outcomes included other liver injury markers (AST, MASEF score, cytokeratin 18, pro-C3).
Main Results
- Betaine at 8, 4, and 2 g/day significantly reduced ALT, AST, cytokeratin 18, pro-C3, and MASEF score.
- The 1 g/day dose did not show significant improvements in liver injury markers.
- Mild, transient gastrointestinal symptoms were reported by approximately 35% of participants.
Conclusions
- Betaine at doses of 2, 4, and 8 g/day for 12-24 weeks is effective in reducing liver injury markers in MASLD.
- Lower doses of betaine demonstrate significant therapeutic potential for managing MASLD.
- Betaine appears safe for treating MASLD, with only mild gastrointestinal side effects noted.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Technological Integration: EUS is a sophisticated integration of optical endoscopy and ultrasonography. The endoscope visualizes the mucosal surface directly, while the ultrasound component penetrates deeper to visualize organs and structures beyond the gastrointestinal wall.
Image Formation: The ultrasound...
Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...